{"paper_id":"1ff25d6f-5bbd-45a6-a116-7c8c28463891","body_text":"Note! Please note that this article is currently available in the Early View stage but represents the final Version of Record (VoR). This is the definitive, fully citable version, which has undergone copyediting, typesetting, metadata assignment, and DOI allocation. The Version of Record (VoR) is considered final and is not subject to further content changes, except for the assignment of volume, issue, and page numbers when it is formally incorporated into a specific journal issue. Despite this, the article already carries complete bibliographic details and can be cited confidently prior to its formal placement in an issue.\nAbstract\nThe chemotherapeutic agent paclitaxel is being presented as a promising antiendometriotic\ntreatment. Endometriosis is a common gynecological disorder that leads to chronic\nperitoneal pain and infertility. It is characterized by the presence of endometrial tissue outside the\nuterus. In this review, the anti-endometriotic features of paclitaxel are analyzed and discussed from\nboth pharmacological and biomolecular perspectives. Paclitaxel acts pharmacologically as a microtubule-\nstabilizing agent, interfering with the cell cycle and preventing the formation of new cells. It\nalso exhibits anti-angiogenic activity, inhibiting the growth of new blood vessels and thereby reducing\nthe vascularization of endometriotic lesions. Moreover, paclitaxel modulates immune responses,\ninducing an anti-inflammatory environment during endometriosis. At the biomolecular level,\npaclitaxel affects important signaling pathways involved in endometriotic pathogenesis. It acts on\nmolecules such as transforming growth factor-beta (TGF-β), vascular endothelial growth factor\n(VEGF), nuclear factor-kappa B (NF-κB), and matrix metalloproteinases (MMPs), which play roles\nin inflammation, neovascularization, and tissue remodeling associated with endometriosis. This review\nprovides detailed insights into the research conducted on paclitaxel, including its safety and efficacy\nas a treatment for endometriosis. It also examines different methods of administration, dosage\nschedules, and combination strategies aimed at enhancing its therapeutic effects. In conclusion,\npaclitaxel represents a potential therapeutic strategy for endometriosis by acting not only through its\npharmacological properties but also through its biomolecular effects on the disease. Additional investigations\nare needed to elucidate its mechanisms of action, determine optimal treatment schedules,\nand explore new combination therapies to improve outcomes in patients with endometriosis.\nKeywords: Paclitaxel, gynecological disorders, endometriosis, apoptosis induction, angiogenesis, biomolecular.\n1","source_license":"CC0","license_restricted":false}